Is Amgen Inc (AMGN) overvalued? · P/E 24, rev $36.75B
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
This page asks whether Amgen Inc (AMGN) looks expensive on cached numbers — not a short thesis.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AMGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AMGN stock page for the full model, not this heading.
Not investment advice.